Patient characteristics by randomized group and genetic risk category
PRS, stroke
ATRIAL FIBRILLATION, STROKE, RENAL DISEASE
After genotyping, imputation, and stringent quality control, 1567 patients were available for the PRS analyses (Consort flow chart of the patients included in the analysis for genetic AF risk. Treatment is shown split by randomized group and by risk groups of PRS AF.Consort flow chart of the patients included in this analysis for genetic stroke risk. Treatment is shown split by randomized group and by risk groups of PRS-stroke.Baseline characteristics of patients in EAST-AFNET4 biosample sub-study receiving either early rhythm control or usual carePresented as mean ± standard deviation, Median and Interquartile range (IQR) or total numbers and percentages in brackets.PRS, polygenic risk score; AF, atrial fibrillation; MoCA, montreal cognitive assessment; MDRD, modification of diet in renal disease; NOAC, non-VKA oral anticoagulant; VKA, vitamin K antagonist; AAD, anti-arrhythmic drug.The distribution of genetic risk followed a normal distribution for each PRS per treatment group (see The same was found in the PRS-stroke